Scrip takes a look at major R&D trends in the Korean biotech sector in the third quarter, analysing new moves at Genexine, Bridge Biotherapeutics, Oscotec and others to cope with ongoing challenges and focus resources on the most promising projects.

Pfizer appears to be maintaining its “opportunistic” approach to biosimilars, having ceased to split out the business unit’s results during its Q3 earnings report.

Prestige says a meeting with the FDA in November represents a “final step” before filing its trastuzumab biosimilar with the US agency by the end of the year. Meanwhile, a major shareholder has invested further in the Singapore-based biosimilars developer.

The European Medicines Agency has delivered its verdict on marketing applications for a raft of new medicines.